TROP2 PET
An experimental PET scan that shows whether a tumour carries the TROP2 protein, so doctors could pick the right ADC before giving it.
89Zr-labelled anti-TROP2 antibodies and 68Ga/18F-labelled TROP2 nanobodies and peptides (Fudan University, Peking Union, others) have been imaged in first-in-human studies in breast, lung, and pancreatic cancer. The goal is non-invasive, whole-body, heterogeneity-aware selection and monitoring for sacituzumab govitecan, datopotamab deruxtecan, and sacituzumab tirumotecan, where IHC has been an unreliable predictor.
How it works
A radiolabelled TROP2 binder is imaged; antibody tracers image at 3-6 days with 89Zr, nanobodies within 1-2 hours with 68Ga/18F.
- Whole-body target map
- Could resolve intratumoural heterogeneity
- Repeatable on progression
- Early stage; no validated SUV cut-off
- Antibody tracers are slow; nanobodies have renal uptake
- Unclear whether expression level predicts ADC response
Latest papers
topQuery for this technology: (TITLE:"TROP2 PET" OR ABSTRACT:"TROP2 PET" OR TITLE:"TROP2 imaging" OR ABSTRACT:"TROP2 imaging" OR TITLE:"Trop-2 PET" OR ABSTRACT:"Trop-2 PET"). Results are unfiltered search hits about TROP2 PET, not a curated reading list.